Supplementary Table 5: Unadjusted and Adjusted hazard ratios of all-cause mortality, and sub-distribution hazard ratios for cancer-specific mortality, for patients diagnosed during 2019 and 2020[1]

	Bladder	Breast	Cervix	Colorectal	Kidney	Lung	Melanoma	NHL	Prostate	Uterus
Unadjusted HR[2]										
2019 cohort[5]	0.94 (0.73, 1.22)	0.98 (0.75, 1.28)	1.65 (0.77, 3.56)	0.87 (0.76, 1.00)	1.14 (0.83, 1.56)	0.99 (0.91, 1.07)	1.12 (0.73, 1.71)	1.03 (0.83, 1.29)	1.18 (0.90, 1.54)	1.00 (0.69, 1.46)
2020 cohort[6]	0.77 (0.56, 1.04)	0.93 (0.69, 1.27)	0.81 (0.30, 2.20)	1.24 (1.08, 1.43)	1.18 (0.83, 1.68)	1.05 (0.96, 1.14)	1.17 (0.72, 1.90)	1.43 (1.14, 1.78)	1.32 (0.98, 1.78)	1.27 (0.87, 1.87)
Adjusted HR[3]										
2019 cohort	0.96 (0.74, 1.25)	0.96 (0.73, 1.25)	1.54 (0.71, 3.35)	0.90 (0.79, 1.04)	1.22 (0.89, 1.68)	0.94 (0.87, 1.02)	1.29 (0.84, 1.98)	1.03 (0.83, 1.29)	1.07 (0.81, 1.40)	1.20 (0.82, 1.76)
2020 cohort	0.86 (0.63, 1.17)	0.87 (0.64, 1.18)	0.57 (0.21, 1.59)	1.21 (1.05, 1.40)	1.06 (0.74, 1.52)	1.03 (0.95, 1.13)	1.23 (0.76, 2.00)	1.43 (1.14, 1.79)	1.13 (0.84, 1.51)	1.57 (1.06, 2.33)
Sub-distribution HR[4]										
2019 cohort	1.00 (0.75, 1.34)	0.91 (0.67, 1.24)	1.55 (0.69, 3.49)	0.92 (0.79, 1.06)	1.30 (0.89, 1.90)	0.94 (0.87, 1.02)	1.69 (1.01, 2.84)	0.96 (0.76, 1.23)	0.97 (0.71, 1.33)	1.19 (0.79, 1.78)
2020 cohort	0.95 (0.68, 1.34)	0.87 (0.61, 1.23)	0.38 (0.12, 1.25)	1.18 (1.01, 1.38)	0.99 (0.65, 1.51)	1.05 (0.96, 1.15)	1.55 (0.86, 2.78)	1.40 (1.11, 1.78)	1.01 (0.71, 1.42)	1.54 (1.02, 2.30)

1: All results were in contrast to the referent group, which were patients diagnosed between Jan 16, 2018 and Mar 15, 2019

2: Hazard ratios were estimated from a univariable Cox regression model

3: Hazard ratios were estimated from a multivariable Cox regression model adjusting for age, sex, residence (urban vs rural), and stage at diagnosis

4: Hazard ratios were estimated from a Fine-Gray model for cancer-specific death, with competing risk of non-cancer related death.

5: The 2019 cohort referred to patients diagnosed between Mar 16, 2019 and Mar 15, 2020.

6: The 2020 cohort referred to patients diagnosed between Mar 16, 2020 and Dec 15, 2020.